TY - JOUR
T1 - Targeted degradation of proteins localized in subcellular compartments by hybrid small molecules
AU - Okuhira, Keiichiro
AU - Shoda, Takuji
AU - Omura, Risa
AU - Ohoka, Nobumichi
AU - Hattori, Takayuki
AU - Shibata, Norihito
AU - Demizu, Yosuke
AU - Sugihara, Ryo
AU - Ichino, Asato
AU - Kawahara, Haruka
AU - Itoh, Yukihiro
AU - Ishikawa, Minoru
AU - Hashimoto, Yuichi
AU - Kurihara, Masaaki
AU - Itoh, Susumu
AU - Saito, Hiroyuki
AU - Naito, Mikihiko
N1 - Funding Information:
This work was supported by Grants-in Aid for Scientific Research from the Japan Society for the Promotion of Science [Grants 25430164, 16K08236, 16H05090, 16K15121], a grant for the Research on Development of New Drugs from Japan Agency for Medical Research and Development (AMED) [Grants 15ak0101029h1402, 16ak0101029j1403], a grant from Suzuken memorial foundation, and a research program for development of intelligent Tokushima artificial exosome (iTEX) from Tokushima University. The authors thank Mariko Seki for technical assistance, and Pacific Edit for reviewing the manuscript prior to submission.
Publisher Copyright:
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.
PY - 2017/3
Y1 - 2017/3
N2 - Development of novel small molecules that selectively degrade pathogenic proteins would provide an important advance in targeted therapy. Recently, we have devised a series of hybrid small molecules named SNIPER (specific and nongenetic IAP-dependent protein ERaser) that induces the degradation of target proteins via the ubiquitin-proteasome system. To understand the localization of proteins that can be targeted by this protein knockdown technology, we examined whether SNIPER molecules are able to induce degradation of cellular retinoic acid binding protein II (CRABP-II) proteins localized in subcellular compartments of cells. CRABP-II is genetically fused with subcellular localization signals, and they are expressed in the cells. SNIPER(CRABP) with different IAP-ligands, SNIPER(CRABP)-4 with bestatin and SNIPER(CRABP)-11 with MV1 compound, induce the proteasomal degradation of wild-type (WT), cytosolic, nuclear, and membrane-localized CRABP-II proteins, whereas only SNIPER(CRABP)-11 displayed degradation activity toward the mitochondrial CRABP-II protein. The small interfering RNA-mediated silencing of cIAP1 expression attenuated the knockdown activity of SNIPER(CRABP) against WT and cytosolic CRABP-II proteins, indicating that cIAP1 is the E3 ligase responsible for degradation of these proteins. Against membrane-localized CRAB-P-II protein, cIAP1 is also a primary E3 ligase in the cells, but another E3 ligase distinct from cIAP2 and X-linked inhibitor of apoptosis protein (XIAP) could also be involved in the SNIPER(CRABP)-11-induced degradation. However, for the degradation of nuclear and mitochondrial CRABP-II proteins, E3 ligases other than cIAP1, cIAP2, and XIAP play a role in the SNIPER-mediated protein knockdown. These results indicate that SNIPER can target cytosolic, nuclear, membrane-localized, and mitochondrial proteins for degradation, but the responsible E3 ligase is different, depending on the localization of the target protein.
AB - Development of novel small molecules that selectively degrade pathogenic proteins would provide an important advance in targeted therapy. Recently, we have devised a series of hybrid small molecules named SNIPER (specific and nongenetic IAP-dependent protein ERaser) that induces the degradation of target proteins via the ubiquitin-proteasome system. To understand the localization of proteins that can be targeted by this protein knockdown technology, we examined whether SNIPER molecules are able to induce degradation of cellular retinoic acid binding protein II (CRABP-II) proteins localized in subcellular compartments of cells. CRABP-II is genetically fused with subcellular localization signals, and they are expressed in the cells. SNIPER(CRABP) with different IAP-ligands, SNIPER(CRABP)-4 with bestatin and SNIPER(CRABP)-11 with MV1 compound, induce the proteasomal degradation of wild-type (WT), cytosolic, nuclear, and membrane-localized CRABP-II proteins, whereas only SNIPER(CRABP)-11 displayed degradation activity toward the mitochondrial CRABP-II protein. The small interfering RNA-mediated silencing of cIAP1 expression attenuated the knockdown activity of SNIPER(CRABP) against WT and cytosolic CRABP-II proteins, indicating that cIAP1 is the E3 ligase responsible for degradation of these proteins. Against membrane-localized CRAB-P-II protein, cIAP1 is also a primary E3 ligase in the cells, but another E3 ligase distinct from cIAP2 and X-linked inhibitor of apoptosis protein (XIAP) could also be involved in the SNIPER(CRABP)-11-induced degradation. However, for the degradation of nuclear and mitochondrial CRABP-II proteins, E3 ligases other than cIAP1, cIAP2, and XIAP play a role in the SNIPER-mediated protein knockdown. These results indicate that SNIPER can target cytosolic, nuclear, membrane-localized, and mitochondrial proteins for degradation, but the responsible E3 ligase is different, depending on the localization of the target protein.
UR - http://www.scopus.com/inward/record.url?scp=85012096156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012096156&partnerID=8YFLogxK
U2 - 10.1124/mol.116.105569
DO - 10.1124/mol.116.105569
M3 - Article
C2 - 27965304
AN - SCOPUS:85012096156
SN - 0026-895X
VL - 91
SP - 159
EP - 166
JO - Molecular Pharmacology
JF - Molecular Pharmacology
IS - 3
ER -